Traditional Chinese medicine in the treatment of diabetic kidney disease: the mechanisms of signaling pathways regulations

Diabetic kidney disease (DKD) represents a diabetes-driven microvascular complication characterized by renal physiological and metabolic disorders and is considered a top-ranking trigger of progression to end-stage renal disease and death in diabetic patients. Although the drugs commonly used in clinical practice for DKD provide some renal protection, their toxic side effects and limited ability to halt further progression of the disease remain unsatisfactory. Traditional Chinese medicine (TCM) brings centuries of accumulated practice and distinct therapeutic strengths to the management of chronic diseases with complex pathogenesis such as DKD. Its characteristics of multi-target and multi-pathway intervention establish a solid material basis for DKD therapy, while its low toxicity profile aligns well with the chronic nature of DKD. This review elaborates on the therapeutic potential of examining TCM's impact on DKD through the prism of cellular signaling pathways and reveals that the Nrf2, TGF-β/Smad, NF-κB/NLRP3, MAPK, and PI3K/AKT signaling pathways warrant particular attention in the TCM treatment of DKD. The TCM agents involved include astragaloside IV, Shengqing Jiangzhuo formula, Huangkui capsule, Fuxin granules, Liuwei Dihuang pill, Taxus chinensis, Burdock fructooligosaccharide, baicalin, hirudin, rutin, and fermented seaweed extracts. This review aims to refresh and consolidate the signaling pathways engaged by TCM in DKD, sift for promising targets and drugs, and supply both conceptual and experimental scaffolding for future anti-DKD therapeutics.

Abstract aus PubMed (NCBI) für den zitierten Eintrag, in der Originalsprache wiedergegeben. Maßgeblich ist die Fassung der Originalpublikation.

Das Abstract wird nicht übersetzt, damit die eigene Wortwahl der Autoren erhalten bleibt.

This review covers traditional Chinese medicine agents — including hirudin, astragaloside IV, baicalin and rutin — in diabetic kidney disease, focusing on the Nrf2, TGF-β/Smad, NF-κB/NLRP3, MAPK and PI3K/AKT signaling pathways.

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Weitere begutachtete Studien in der Kategorie „Speichel-Pharmakologie“.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Leech Salivary Proteome and Transcriptome: 434 Deduced Protein Sequences — Liu Z, Tong X, Su Y, et al. (2019)
• Medicinal Leech Draft Genome — Anticoagulant Gene Survey — Kvist S, Manzano-Marín A, de Carle D, Trontelj P, Siddall ME (2020)
• Auswirkungen der Hirudotherapie auf Leberfunktionen, Lipidprofil und Insulinsensitivität bei Ratten mit metabolischem Syndrom — Bilden A et al. (2026)
• Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial — Abtahi-Forooshani M et al. (2026)
• Medicinal leeches and hirudotherapy — Gödekmerdan A et al. (2011)
• PEROXIDATION OF SALIVA LIPIDS IN PATIENTS WITH POSTCOVID SYNDROME DURING HIRUDOTHERAPY — Serikbayeva S et al. (2024)
• Medicinal leech therapy in pain syndromes: a narrative review — Koeppen D, Aurich M, Rampp T (2014)
• Leech therapy in the treatment of a penile haematoma in a stallion — Nowicki A, Jaworska J, Baranski W (2021)
• Leech therapy (Hirudo medicinalis) attenuates testicular damages induced by testicular ischemia/reperfusion in an animal model — Davoodi F et al. (2021)

Alle von der ASH analysierten Studien →